Experience of using the new ultrafast-acting insulin Fiasp® in patients on insulin pump therapy: a case report


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Currently, insulin pump therapy (IPT) is one of the most progressive methods of treating diabetes mellitus. Over the past decades, IPT has not only improved technically, but also become more available. At the same time, it is obvious that the better exogenous insulin mimics physiological secretion, the better glycemic control in diabetic patients. The need to develop insulin that better mimics endogenous insulin secretion led to the development of ultra fast-acting insulin aspart (Fiasp®) by Novo Nordisk A/S., Denmark. Description of the clinical case. This case report demonstrates that the patient was switched to IPT using a new ultrafast-acting insulin aspart (Fiasp) from the a multiple insulin injection regimen (insulin detemir, insulin aspart), which significantly improved glycemic control and thereby improved the prognosis of the DM1 course. Conclusion. Taking into account the pharmacokinetic features of ultrafast insulin, it seems reasonable to use it in pump insulin therapy to achieve better results in glycemic control.

Full Text

Restricted Access

About the authors

Ilya A. Barsukov

M.F. Vladimirsky Moscow Regional Research Clinical Institute

Email: palantirr@inbox.ru
Cand. Sci. (Med.), Senior Researcher at the Department of Therapeutic Endocrinology 61/2 Shchepkina St., Moscow 129110, Russian Federation

A. A Demina

M.F. Vladimirsky Moscow Regional Research Clinical Institute

Moscow, Russia

References

  1. Chow N.,Shearer D., Tiidesiey H.G.,et al. Determining starting basal rates of insulin infusion for insulin pump users: a comparison between methods. BMJ. Open Diab Res Care. 2016;4(1):e000145. doi: 10.1136/bmjdrc-2015-000145.
  2. Bruttomesso D., Costa S., Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: stiill the best option for insulin therapy. Diab Metab Res Rev. 2009;25:99-111. doi: 10.1002/dmrr.931.
  3. Reznik Y., Cohen O., Aronson R., et ai. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled triai. Lancet. 2014;384:1265-72. doi: 10.1016/S0140-6736(14)61037-0.
  4. Pickup J, Mattock M., Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlied triais. BMJ. 2002;324(7339):705. doi: 10.1136/bmj.324.7339.705.
  5. Дедов И.И., Шестакова М.В. Сахарный диабет типа 1: реалии и перспективы. М., 2016. 504 с.
  6. Bode B.W., Davidson P.C., Fredrickson L.P, et ai. Diabetes management in the new millennium using insulin pump therapy. Diab Metab Res Rev. 2002;18(Suppi. 1):S14-20. doi: 10.1002/dmrr.205.
  7. Hoogma R.P., Hammond P.J., Gomis R., et ai. Comparison of the effects of continuous subcutaneous insuiln infusion (CSII) and NPH-based mulipie daliy insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diab Med. 2006;23(2):141-47. doi: 10.1111/j.1464-5491.2005.01738.x.
  8. Luijf Y.M., van Bon A.C., Hoekstra J.B., et ai. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diab Care 2010;33:2152-55. doi: 10.2337/dc10-0692.
  9. Liiiy E. Humaiog (insulin iispro): Summary of Product Characteristics [article online]. URL: www. ema.europa.eu/docs/en.GB/document_library/EPARProduct_Information/human/000088/WC500050332.pdf (accessed February 21, 2021).
  10. Novo Nordisk. NovoRapid (insulin aspart): Summary of Product Characteristics [article online]. URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000258/WC500030372.pdf (accessed February 21, 2021).
  11. Sanofi-aventis. Apidra (insuiln glulisine): Summary of Product Characteristics [articie oniine]. URL: www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/000557/WC500025250.pdf (accessed February 21, 2021).
  12. Owens D.R., Zinman B., Bolli G.B. Insulins today and beyond. Lancet. 2001;358:739-46. doi: 10.1016/S0140-6736(01)05842-1.
  13. Cobry E., McFann K., Messer L., et ai. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diab Technol Ther. 2010;12:173-77. doi: 10.1089/dia.2009.0112.
  14. Scaramuzza A.E., Iafusco D., Santoro L., et al. Timing of bolus in children with type 1 diabetes using continuous subcutaneous insulin infusion (TiBoDi Study). Diab Technol Ther. 2010;12:149-52. doi: 10.1089/dia.2009.0117.
  15. Heinemann L., Muchmore D.B. Ultrafast-acting insulins: state of the art. J Diab Sci Technol 2012;6:728-42. doi: 10.1177/193229681200600402.
  16. James M.L., Green L., Amiel S.A., et al. Evaluation of the effect of carbohydrate intake on postprandial glucose in patients with type 1 diabetes treated with insulin pumps. J Diab Sci Technol. 2016. doi: 10.1177/1932296816646797.
  17. Ei-Khatib F.H., Russeii S.J., Nathan D.M., et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2:27ra27. doi: 10.1126/scitranslmed.3000619.
  18. Luijf Y.M., DeVries J.H., Zwinderman K., et al. Day and night closed-loop control in aduits with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient selfmanagement. Diab Care 2013;36:3882-87. doi: 10.2337/dc12-1956.
  19. Russeill S.J., Ei-Khatib F.H., Nathan D.M., et al. Biood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diab Care 2012;35:2148-55. doi: 10.2337/dc12-0071.
  20. Bode B.W., Johnson J.A., Hyveied L., et al. Improved Postprandial glycemic control with Faster-Acting insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous insulin Infusion. Diab Technol Ther. 2017;19(1):25-33. Doi: 10.1089/ dia.2016.0350.
  21. Heise T., Pieber T.R., Danne T., et al. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in aduits with type 1 diabetes. Ciin Pharmacokinet. 2017;56(5):551-59. doi: 10.1007/s40262-017-0514-8.
  22. Russeii-Jones D., Bode B.W., De Biock C., et al. Fast-Acting insulin Aspart Improves glycemic control in Basall-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Triail (onset 1). Diab Care. 2017;40(7):943-50. doi: 10.2337/dc16-1771.
  23. Bowering K., Case C., Harvey J., Reeves M., et ai. Faster Aspart Versus insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diab Care. 2017;40(7):951-57. doi: 10.2337/dc16-1770.
  24. Kionoff D.C., Evans M.L., Lane W., et al. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in aduits with type 1 diabetes (onset 5). Diab Obes Metab. 2019;21(4):961-67. doi: 10.1111/dom.13610.
  25. Fiasp (insulin aspart) prescribing information. Bagsvaerd: Novo Nordisk; 2017.
  26. Fath M., Danne T., Biester T., et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr Diab. 2017;18:903-10. doi: 10.1111/pedi.12506.
  27. Battellno T., Danne T., Bergenstal R.M., et al. clinical Targets for Continuous Giucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diab Care. 2019;42(8):1593-603. doi: 10.2337/dci19-0028.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies